Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA; Ahmanson/UCLA Adult Congenital Heart Disease Center, University of California, Los Angeles, California, USA.
Division of Cardiology, Department of Medicine, University of California, Los Angeles, California, USA.
J Am Coll Cardiol. 2024 Feb 20;83(7):726-738. doi: 10.1016/j.jacc.2023.12.005.
The molecular mechanisms underlying Fontan-associated liver disease (FALD) remain largely unknown.
This study aimed to assess intrahepatic transcriptomic differences among patients with FALD according to the degree of liver fibrosis and clinical outcomes.
This retrospective cohort study included adults with the Fontan circulation. Baseline clinical, laboratory, imaging, and hemodynamic data as well as a composite clinical outcome (CCO) were extracted from medical records. Patients were classified into early or advanced fibrosis. RNA was isolated from formalin-fixed paraffin-embedded liver biopsy samples; RNA libraries were constructed with the use of an rRNA depletion method and sequenced on an Illumina Novaseq 6000. Differential gene expression and gene ontology analyses were performed with the use of DESeq2 and Metascape.
A total of 106 patients (48% male, median age 31 years [IQR: 11.3 years]) were included. Those with advanced fibrosis had higher B-type natriuretic peptide levels and Fontan, mean pulmonary artery, and capillary wedge pressures. The CCO was present in 23 patients (22%) and was not predicted by advanced liver fibrosis, right ventricular morphology, presence of aortopulmonary collaterals, or Fontan pressures on multivariable analysis. Samples with advanced fibrosis had 228 upregulated genes compared with early fibrosis. Samples with the CCO had 894 upregulated genes compared with those without the CCO. A total of 136 upregulated genes were identified in both comparisons and were enriched in cellular response to cytokine stimulus or oxidative stress, VEGFA-VEGFR2 signaling pathway, TGF-β signaling pathway, and vasculature development.
Patients with FALD and advanced fibrosis or the CCO exhibited upregulated genes related to inflammation, congestion, and angiogenesis.
Fontan 相关肝疾病(FALD)的分子机制在很大程度上尚不清楚。
本研究旨在根据肝纤维化程度和临床结局评估 FALD 患者的肝内转录组差异。
这项回顾性队列研究纳入了 Fontan 循环的成人患者。从病历中提取基线临床、实验室、影像学和血液动力学数据以及复合临床结局(CCO)。患者分为早期或晚期纤维化。从福尔马林固定石蜡包埋的肝活检样本中分离 RNA;使用 rRNA 耗竭方法构建 RNA 文库,并在 Illumina Novaseq 6000 上进行测序。使用 DESeq2 和 Metascape 进行差异基因表达和基因本体分析。
共纳入 106 例患者(48%为男性,中位年龄 31 岁[IQR:11.3 岁])。晚期纤维化患者的 B 型利钠肽水平和 Fontan、肺动脉平均压和毛细血管楔压较高。23 例患者(22%)存在 CCO,多变量分析显示,晚期肝纤维化、右心室形态、存在体肺侧支循环或 Fontan 压力均不能预测 CCO。与早期纤维化相比,晚期纤维化的样本有 228 个上调基因。与无 CCO 的样本相比,有 CCO 的样本有 894 个上调基因。在这两种比较中,共鉴定出 136 个上调基因,这些基因富集于细胞对细胞因子刺激或氧化应激的反应、VEGFA-VEGFR2 信号通路、TGF-β 信号通路和血管发育。
患有 FALD 和晚期纤维化或 CCO 的患者表现出与炎症、淤血和血管生成相关的上调基因。